Alcohol Use Disorders

  • Laura Orsolini
  • Cesario Bellantuono
  • Domenico De Berardis
  • Fabrizio Schifano


Alcohol use disorder (AUD) during pregnancy and postpartum period may determine congenital malformations or later intellectual disability as well as determine an increased risk of foetal alcohol syndrome (FAS) or foetal alcohol spectrum disorders (FASDs). Unfortunately, there is little research information and clinical studies to date available regarding clinical decision-making and therapeutic flow chart able to give practical and ready clinical guidelines to clinicians working within mental health and drug addiction’s services in the management and treatment of pregnant and/or nursing women affected with AUD. Little evidence is available in the treatment and management of alcohol withdrawal during pregnancy and in the administration of acamprosate, naltrexone and disulfiram as well. Overall, clinicians working in the field of mental health and addictions should advise women who are pregnant or planning a pregnancy at risk of AUD that not drinking is the safest option to limit/reduce the risk of foetal malformations, perinatal and/or obstetrician complications and limit the risks on newborns.


Alcohol Alcohol use disorders Pregnancy Perinatal period Foetal alcohol spectrum disorders (FASDs) Foetal alcohol syndrome (FAS) 


  1. 1.
    Substance Abuse and Mental Health Services Administration. Results from the 2012 national survey on drug use and health: summary of national findings. NSDUH Series H-46, HHS Publication No. (SMA) 13–4795. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013.Google Scholar
  2. 2.
    Department of Health. Clinical practice guidelines: pregnancy care. Short form guideline. Canberra, ACT: Australian Government Department of Health; 2018.Google Scholar
  3. 3.
    NHMRC. Australian guidelines to reduce health risks from drinking alcohol. National Health and Medical Research Council: Canberra, ACT; 2009.Google Scholar
  4. 4.
    Alvik A, Heyerdahl S, Haldorsen T, Lindemann R. Alcohol use before and during pregnancy: a population-based study. Acta Obstet Gynecol. 2006;85:1292–8.CrossRefGoogle Scholar
  5. 5.
    Carter D, Kostaras X. Psychiatric disorders in pregnancy. BCMJ. 2005;47(2):96–9.Google Scholar
  6. 6.
    Hendrick V, editor. Disorders in pregnancy and the postpartum. Principles and treatment. Totowa, NJ: Humana; 2006.Google Scholar
  7. 7.
    Lemoine P. The history of alcoholic fetopathies. J Popul Ther Clin Pharmacol. 2012;19(2):224–6.Google Scholar
  8. 8.
    Lemoine P, Harousseau H, Borteyru JP, Menuet JC. Children of alcoholic parents-observed anomalies: discussion of 127 cases. Ouest Med. 1968;8:476–82.Google Scholar
  9. 9.
    Jones KL, Smith DW, Ulleland CN, Streissguth AP. Pattern of malformation in offspring of chronic alcohol mothers. Lancet. 1973;301(7815):1267–71.CrossRefGoogle Scholar
  10. 10.
    Blume SB. Is social drinking during pregnancy harmless? There is reason to think not. Adv Alcohol Subst Abuse. 1985;5(1–2):209.CrossRefGoogle Scholar
  11. 11.
    O’Callaghan FV, O’Callaghan M, Najman JM, Williams GM, Bor W. Prenatal alcohol exposure and attention, learning and intellectual ability at 14 years: a prospective longitudinal study. Early Hum Dev. 2007;83(2):115–23.CrossRefGoogle Scholar
  12. 12.
    Patra J, Bakker R, Irving H, Jaddoe VWV, Malini S, Rehm J. Dose-response relationship between alcohol consumption before and during pregnancy and the risks of low birth weight, preterm birth and small-size-for-gestational age (SGA) – a systematic review and meta-analysis. BJOG. 2011;118(12):1411–21.CrossRefGoogle Scholar
  13. 13.
    Sayal K, Heron J, Golding J, Emond A. Prenatal alcohol exposure and gender differences in childhood mental health problems: a longitudinal population-base study. Pediatrics. 2007;119(2):e426–34.CrossRefGoogle Scholar
  14. 14.
    Sood B, Delaney-Black V, Covington C, Nordstrom-Klee B, Ager J, Templin T, Janisse J, Martier S, Sokol RJ. Prenatal alcohol exposure and childhood behavior at age 6 to 7 years: I. dose-response effect. Pediatrics. 2001;108(2):e34.CrossRefGoogle Scholar
  15. 15.
    Streissguth AP, Sampson PD, Barr HM. Neurobehavioral dose-response effects of prenatal alcohol exposure in humans from infancy to adulthood. Ann N Y Acad Sci. 1989;562:145–58.CrossRefGoogle Scholar
  16. 16.
    Hoyme HE, Kalberg WO, Elliott AJ, Blankenship J, Buckley D, Marais AS, Manning MA, Robinson LK, Adam MP, Abdul-Rahman O, Jewett T, Coles CD, Chambers C, Jones KL, Adnams CM, Shah PE, Riley EP, Charness ME, Warren KR, May PA. Updated clinical guidelines for diagnosing fetal alcohol spectrum disorders. Pediatrics. 2016;138:e20154256.CrossRefGoogle Scholar
  17. 17.
    Murawski NJ, Moore EM, Thomas JD, Riley EP. Advances in diagnosis and treatment of fetal alcohol spectrum disorders: from animal models to human studies. Alcohol Res. 2015;37:97–108.PubMedPubMedCentralGoogle Scholar
  18. 18.
    May PA, Baete A, Russo J, Elliott AJ, Blankenship J, Kalberg WO, Buckley D, Brooks M, Hasken J, Abdul-Rahman O, Adam MP, Robinson LK, Manning M, Hoyme HE. Prevalence and characteristics of fetal alcohol spectrum disorders. Pediatrics. 2014;134:855–66.CrossRefGoogle Scholar
  19. 19.
    May PA, Blankenship J, Marais AS, et al. Approaching the prevalence of the full spectrum of fetal alcohol spectrum disorders in a South African population-based study. Alcohol Clin Exp Res. 2013;37:818–30.CrossRefGoogle Scholar
  20. 20.
    May PA, Fiorentino D, Coriale G, Kalberg WO, Hoyme HE, Aragón AS, Buckley D, Stellavato C, Gossage JP, Robinson LK, Jones KL, Manning M, Ceccanti M. Prevalence of children with severe fetal alcohol spectrum disorders in communities near Rome, Italy: new estimated rates are higher than previous estimates. Int J Environ Res Public Health. 2011;8:2331–51.CrossRefGoogle Scholar
  21. 21.
    Riley EP, Infante MA, Warren KR. Fetal alcohol spectrum disorders: an overview. Neuropsychol Rev. 2011;21(2):73–8.CrossRefGoogle Scholar
  22. 22.
    Popova S, Lange S, Shield K, Mihic A, Chudley AE, Mukherjee RAS, Bekmuradov D, Rehm J. Comorbidity of fetal alcohol spectrum disorder: a systematic review and meta-analysis. Lancet. 2016;387:978–87.CrossRefGoogle Scholar
  23. 23.
    Ewing JA. Detecting alcoholism: the CAGE questionnaire. JAMA. 1984;252:1905–7.CrossRefGoogle Scholar
  24. 24.
    Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption—II. Addiction. 1993;88:791–804.CrossRefGoogle Scholar
  25. 25.
    Selzer ML. The Michigan Alcoholism Screening Test: the quest for a new diagnostic instrument. Am J Psychiatry. 1971;127(12):89–94.CrossRefGoogle Scholar
  26. 26.
    Russel M, Martier SS, Sokol RJ, Mudar P, Bottoms S, Jacobson S, Jacobson J. Screening for pregnancy risk-drinking. Alcohol Clin Exp Res. 1994;18(5):1156–61.CrossRefGoogle Scholar
  27. 27.
    Chang G, Wilkins-Haug L, Berman S, Goetz MA, Behr H, Hiley A. Alcohol use and pregnancy: improving identification. Obstet Gynecol. 1998;91:892–8.PubMedGoogle Scholar
  28. 28.
    Graham K, Wilsnack R, Dawson D, Vogeltanz N. Should alcohol consumption measures be adjusted for gender differences? Addiction. 1998;93:1137–47.CrossRefGoogle Scholar
  29. 29.
    Jones TB, Bailey BA, Sokol RJ. Alcohol use in pregnancy: insights in screening and intervention for the clinician. Clin Obstet Gynecol. 2013;56(1):114–23.CrossRefGoogle Scholar
  30. 30.
    Urbano-Marquez A, Estruch R, Fernandez-Sola J. The greater risk of alcoholic cardiomyopathy and myopathy in women compared with men. JAMA. 1995;274:149–54.CrossRefGoogle Scholar
  31. 31.
    Harris BS, Bishop KC, Kemeny HR, Walker JS, Rhee E, Kuller JA. Risk factors for birth defects. Obstet Gynecol Surv. 2017;72(2):123–35.CrossRefGoogle Scholar
  32. 32.
    Huang J, Zhu T, Qu Y, Mu D. Prenatal, perinatal and neonatal risk factors for intellectual disability: a systemic review and meta-analysis. PLoS One. 2016;11(4):e0153655. 2016 27110944.CrossRefGoogle Scholar
  33. 33.
    Gupta KK, Gupta VK, Shirasaka T. An update on fetal alcohol syndrome—pathogenesis, risks, and treatment. Alcohol Clin Exp Res. 2016;40(8):1594–602.CrossRefGoogle Scholar
  34. 34.
    Briggs GG, Freeman RK. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins Health; 2015.Google Scholar
  35. 35.
    Mitchell AA, Gilboa SM, Werler MM, et al. National birth defects prevention study: medication use during pregnancy, with particular focus on prescription drugs: 1976–2008. Am J Obstet Gynecol. 2011;205(1):51.e1–8.CrossRefGoogle Scholar
  36. 36.
    APA (American Psychiatric Association). Practice guideline for the pharmacological treatment of patients with alcohol use disorder. Washington, DC: APA Press; 2018.Google Scholar
  37. 37.
    Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010;8(12):CD001867.Google Scholar
  38. 38.
    Zagon IS, Tobias SW, Hytrek SD, McLaughlin PJ. Opioid receptor blockade throughout prenatal life confers long-term insensitivity to morphine and alters mu opioid receptors. Pharmacol Biochem Behav. 1998;59:201–7.CrossRefGoogle Scholar
  39. 39.
    Kelty E, Hulse G. A retrospective cohort study of birth outcomes in neonates exposed to naltrexone in utero: a comparison with methadone-, buprenorphine- and non-opioid-exposed neonates. Drugs. 2017;77(11):1211–9.CrossRefGoogle Scholar
  40. 40.
    Helmbrecht GD, Hoskins IA. First trimester disulfiram exposure: report of two cases. Am J Perinatol. 1993;10(1):5–7.CrossRefGoogle Scholar
  41. 41.
    Nora H, Nora J, Blu J. Limb reduction anomalies in infants born to disulfiram-treated alcohol mothers. Lancet. 1977;3:664–9.CrossRefGoogle Scholar
  42. 42.
    Reitnauer PJ, Callanan NP, Farber RA, Aylsworth AS. Prenatal exposure to disulfiram implicated in the cause of malformations in discordant monozygotic twins. Teratology. 1997;56(6):358–62.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Laura Orsolini
    • 1
    • 2
    • 3
  • Cesario Bellantuono
    • 4
  • Domenico De Berardis
    • 3
    • 5
    • 6
  • Fabrizio Schifano
    • 2
  1. 1.KOS Care S.r.L., Neomesia Mental HealthVilla Jolanda HospitalSciscianoItaly
  2. 2.Psychopharmacological, Drug Misuse and Novel Psychoactive Substances Research UnitSchool of Life and Medical Sciences, University of HertfordshireHatfieldUK
  3. 3.Polyedra ResearchTeramoItaly
  4. 4.DeGra Clinic for Perinatal Mental DisordersVeronaItaly
  5. 5.NHS, Department of Mental Health, Psychiatric Service of Diagnosis and TreatmentHospital “G. Mazzini”TeramoItaly
  6. 6.Department of Neurosciences and ImagingUniversity “G. D’Annunzio”ChietiItaly

Personalised recommendations